1:24
EBMT 2017 | Only the beginning of precision medicine and multiple myeloma.
Irene Ghobrial
1:47
EBMT 2017 | Predicting and preventing clonal evolution in multiple myeloma
Irene Ghobrial
4:58
EBMT 2017 | Concerns about using social media in oncology
Naveen Pemmaraju
4:01
EBMT 2017 | Allogeneic transplant is not the quintessential treatment for ALL anymore!
Sebastian Giebel
3:14
EBMT 2017 | Advantages of chemotherapy and hypomethylating agents in myelodysplastic syndrome
Maria Teresa Voso
1:26
EBMT 2017 | Cellular therapy: a key part of EBMT 2017
Nicolaus Kröger
2:00
EBMT 2017 | Updates on treatment methods for Hodgkin Lymphoma
Stephen Robinson
2:05
EBMT 2017 | Autologous stem cell transplantations: BEAM or BEAC?
Stephen Robinson
1:24
EBMT 2017 | Treatment methods in mantle cell lymphoma
Stephen Robinson
3:26
EBMT 2017 | What are the differences in health technology assessment (HTA) across Europe?
Jean-Luc Harousseau
6:43
EBMT 2017 | How can clinicians and nurses care for patients with oral graft-versus-host disease (GvHD)?
Nathaniel Treister
2:40
EBMT 2017 | Can the cytomegalovirus be predicted by ELISpot assays?
Roy Chemaly
2:36
EBMT 2017 | Transplantation versus novel therapies in high-risk chronic lymphoblastic leukemia (CLL)?
John Gribben
3:44
EBMT 2017 | Is double autologous transplantation in multiple myeloma superior in the age of new agents?
Jean-Luc Harousseau
1:50
EBMT 2017 | Waldenström’s macroglobulinemia: Treatment methods and clonal evolution
Irene Ghobrial
2:19
EBMT 2017 | Highlights from the EBMT 2017 cell therapy day
Christian Chabannon
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals